The Q4 group of serum albumin concentrations was associated with a 3.6-times higher risk of long-term mortality compared to the Q1-3 groups (49.9% vs 15.8%) after pacemaker implantation.
Cohort (n=1,798)
Does serum albumin concentration predict long-term all-cause mortality in patients undergoing permanent pacemaker implantation?
Serum albumin concentration at the time of permanent pacemaker implantation is a strong independent predictor of long-term all-cause mortality.
Effect estimate: 3.6-times higher risk
Absolute Event Rate: 49.9% vs 15.8%
Background: This investigation aims to examine the prognostic utility of albumin concentrations for long-term all-cause mortality in patients undergoing permanent pacemaker implantation. Methods: A total of 1798 patients who received permanent pacemaker implantation were divided into quartiles according to serum albumin concentrations. The significance of albumin in predicting long-term mortality was compared in these quartiles. Results: There was a higher rate of long-term mortality in the Q4 group compared with the Q1–3 groups (49.9 vs 15.8%). The risk of long-term mortality in the Q4 group was 3.6-times higher compared with the Q1–3 groups after adjustment for confounders. Conclusion: Serum albumin level at the time of device implantation has great value when assessing long-term mortality in patients with permanent pacemakers.
Hayıroğlu et al. (Wed,) conducted a cohort in Patients undergoing permanent pacemaker implantation (n=1,798). Serum albumin concentrations (Q4 group) vs. Q1-3 groups was evaluated on Long-term all-cause mortality (3.6-times higher risk). The Q4 group of serum albumin concentrations was associated with a 3.6-times higher risk of long-term mortality compared to the Q1-3 groups (49.9% vs 15.8%) after pacemaker implantation.